|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500111307 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-29 14:52:06 |
|
注册时间: Date of Registration: |
2025-10-29 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
色氨酸饮食护理对代谢相关脂肪性肝病患者的影响 |
|
Public title: |
Effect of tryptophan diet nursing on patients with metabolically related fatty liver disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
色氨酸饮食护理对代谢相关脂肪性肝病患者的影响 |
|
Scientific title: |
Effect of tryptophan diet nursing on patients with metabolically related fatty liver disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李佳 |
研究负责人: |
衡春妮 |
|
Applicant: |
Li Jia |
Study leader: |
Heng Chunni |
|
申请注册联系人电话: Applicant telephone: |
+86 177 9151 5873 |
研究负责人电话: Study leader's telephone: |
+86 137 7210 0470 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
17791515873@163.com |
研究负责人电子邮件: Study leader's E-mail: |
bingao0726@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市新城区长乐西路169号 |
研究负责人通讯地址: |
陕西省西安市灞桥区新寺路569号 |
|
Applicant address: |
169 Changle West Road, Xincheng District, Xi 'an City, Shaanxi Province |
Study leader's address: |
No. 569, Xinsi Road, Baqiao District, Xi 'an City, Shaanxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
空军军医大学 |
||
|
Applicant's institution: |
Air Force Medical University |
||
|
研究负责人所在单位: |
第四军医大学唐都医院 |
||
|
Affiliation of the Leader: |
Tangdu Hospital of the Fourth Military Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
第K202504-41号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
第四军医大学唐都医院医学伦理委员会 |
||
|
Name of the ethic committee: |
IEC of Institution for National Drug Clinical Trials, Tangdu Hospital, Fourth Military Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-23 00:00:00 |
||
|
伦理委员会联系人: |
李诗草 |
||
|
Contact Name of the ethic committee: |
Li Shicao |
||
|
伦理委员会联系地址: |
西安市灞桥区新寺路569号第四军医大学唐都医院药剂科新办公楼304室 |
||
|
Contact Address of the ethic committee: |
Room 304, New Office Building of the Pharmacy Department, Tangdu Hospital, Fourth Military Medical University, No. 569, Xansi Road, Baqiao District, Xi 'an City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 29 8471 7761 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
第四军医大学唐都医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tangdu Hospital of the Fourth Military Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省西安市灞桥区新寺路569号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 569, Xinsi Road, Baqiao District, Xi 'an City, Shaanxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
人才经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Talent fund |
||||||||||||||||||||||
|
Target disease: |
Metabolic-associated fatty liver disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
阐明色氨酸与MAFLD的相关性 |
||||||||||||||||||||||
|
Objectives of Study: |
To elucidate the correlation between tryptophan and MAFLD |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.病例组: (1)纳入标准: 1)年龄≥18岁 2)根据腹部彩超或CT提示存在脂肪肝 3)根据《代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)》标准,确诊为 MAFLD 的患者 4)长期(>1年)在西安市居住的居民 5)本人自愿参加本次研究,且同意签署知情同意书 6)可以与人进行正常交流,同时有良好的依从性 2.对照组: (1)纳入标准: 1)年龄为≥18岁 2)本人自愿参加本次研究,且同意签署知情同意书 3)可以与人进行正常交流,同时有良好的依从性 4)符合病例排除标准的、过往有脂肪肝病史的均不纳入 5)按病例的性别、年龄(±5 周岁)进行匹配,选取同期彩超检查无脂肪肝影像学变化者 6)无饮酒史或饮酒量折合乙醇量<140g/周(女性<70g/周) 7)在西安本地居住一年以上,汉族 |
||||||||||||||||||||||
|
Inclusion criteria |
Case group: 1. Age >=18 years old; 2. Fatty liver is indicated by abdominal color Doppler ultrasound or CT; 3. Patients diagnosed with MAFLD according to the "Guidelines for the Prevention and Treatment of Metabolism-related (Non-Alcoholic) Fatty Liver Disease (2024 Edition)"; 4. Residents who have been residing in Xi 'an for a long time (more than one year); 5. I voluntarily participate in this research and agree to sign the informed consent form; 6. Be able to communicate normally with others and have good compliance at the same time; Control group: 1. The age is >=18 years old; 2. I voluntarily participate in this research and agree to sign the informed consent form; 3. Be able to communicate normally with others and have good compliance at the same time; 4. Those who meet the case exclusion criteria and have a history of fatty liver disease in the past are not included; 5. Matches were made based on the gender and age (+/-5 years old) of the cases, and those without imaging changes of fatty liver in the color Doppler ultrasound examination during the same period were selected; 6. No history of alcohol consumption or the amount of alcohol consumed converted to ethanol is less than 140g per week (less than 70g per week for women); 7. Have resided in Xi 'an for more than one year and be of Han ethnicity; |
||||||||||||||||||||||
|
排除标准: |
1.病例组: 1)其他原因引起的肝脏疾病,如乙型或丙型病毒性肝炎、药物性肝病、遗传性疾病、酒精性肝病等 2)伴有其他重大疾病者(如恶性肿瘤、严重的心脏疾病、肾脏疾病等) 3)妊娠及哺乳期妇女 4)患有精神类疾病 5)不配合调查信息采集 6)近一年服用过色氨酸补充剂/复合多维补充剂 7)过量饮酒(乙醇摄入量男性≥140g/w和女性>70g/w) 8)饮食数据缺失者 9)近两个月改变过生活习惯者,包括饮食习惯、饮酒习惯、吸烟习惯、运动习惯以及睡眠习惯 10)有心血管系统疾病病史及癌症病史者 11)有 MAFLD 病史者 2.对照组: 1)孕妇或哺乳期妇女 2)有其他重大疾病患者 3)不配合信息采集者 4)近一年服用过色氨酸补充剂/复合多维补充剂 |
||||||||||||||||||||||
|
Exclusion criteria: |
Case group: 1.Liver diseases caused by other reasons, such as hepatitis B or C, drug-induced liver diseases, genetic diseases, alcoholic liver diseases, etc; 2. Those with other major diseases (such as malignant tumors, severe heart diseases, kidney diseases, etc.); 3. Pregnant and lactating women; 4. Suffering from mental disorders; 5. Failure to cooperate with the collection of investigation information; 6. Have taken tryptophan supplements/multivitamin supplements in the past year; 7. Excessive alcohol consumption (ethanol intake ≥140g/w for men and >70g/w for women); 8. Those with missing dietary data; 9. Those who have changed their living habits in the past two months, including dietary habits, drinking habits, smoking habits, exercise habits and sleep habits; 10. Those with a history of cardiovascular diseases and cancer; 11. Those with a history of MAFLD. Control group: 1. Pregnant or lactating women; 2. There are patients with other serious diseases; 3. Those who do not cooperate with information collection; 4. Have taken tryptophan supplements/multivitamin supplements in the past year. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-02-17 00:00:00至 To 2026-02-17 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-05-07 00:00:00 至 To 2026-02-17 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
在系列研究结束后(预计 2026 年 2 月 16 日),我们会将数据一并上传至《国家基础科学数据共享服务平台》,网址:https://www.cstcloud.cn/resources/104 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the series of studies is concluded (expected on February 16, 2026), we will upload all the data to the National Basic Science Data Sharing Service Platform at https://www.cstcloud.cn/resources/104. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表,电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF;Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |